The Mission

The company’s mission is to develop novel drugs with delivery technology that will greatly reduce the cost burden to healthcare funders and services as well as substantially improving the quality of life of patients with bladder disorders.

This will be achieved by developing a range of therapeutic drugs based on patients’ needs and lifestyles, which will be delivered through this novel cost effective drug delivery system. The company anticipates an early product uptake as was experienced with the successful Atropine Study carried out by Professor Glickman et al, funded by the MS Society in 20071.